Drug Trial Radar · NCT05852691
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Jul 18, 2023
Primary completion
Oct 15, 2026
Study completion Oct 15, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple-negative breast cancer (TNBC).
Conditions
- Breast Cancer
Interventions
TobemstomigDrug
Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
PembrolizumabDrug
Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Nab-PaclitaxelDrug
Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)
Locations
36 sites in 16 countries. Site status is shown where the registry gives one.
Cancer Blood and Specialty Clinic
Los Alamitos, California
Memorial Sloan-Kettering Cancer Center
New York, New York
Novant Health Presbyterain Medical Center
Charlotte, North Carolina
Avera Cancer Institute
Sioux Falls, South Dakota
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, Argentina
Sunshine Hospital
St Albans, Victoria, Australia
Hospital Araujo Jorge
Goiânia, Goiás, Brazil
Hospital do Cancer de Pernambuco - HCP
Recife, Pernambuco, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
São Paulo, São Paulo, Brazil
Fakultni Thomayerova nemocnice
Praha 4 - Krc, Czechia
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH
Essen, Germany
Dres. Andreas Köhler und Roswitha Fuchs
Langen, Germany
Universitätsklinikum Ulm Am Michelsberg
Ulm, Germany
Komarom-Eszergom Varmegyei Szent Borbala Korhaz
Tatabánya, Hungary
Hadassah University Hospital - Ein Kerem
Jerusaelm, Israel
Sheba Medical Center
Ramat Gan, Israel
Ospedale Provinciale Santa Maria Delle Croci
Ravenna, Emilia-Romagna, Italy
Ospedale San Raffaele
Milan, Lombardy, Italy
Health Pharma Professional Research
Mexico City, Mexico CITY (federal District), Mexico
OncoMed
Mexico City, Mexico CITY (federal District), Mexico
Centro Médico Zambrano Hellion
Monterrey, Nuevo León, Mexico
Centro Medico Monte Carmelo
Arequipa, Peru
Oncosalud Sac
Lima, Peru
Instituto Nacional de Enfermedades Neoplasicas
Lima, Peru
Instituto Peruano de Oncología y Radioterapia
Lima, Peru
?wi?tokrzyskie Centrum Onkologii
Kielce, Poland
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
Krakow, Poland
Medical Oncology Centre of Rosebank
Johannesburg, South Africa
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Gangnam Severance Hospital, Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Quiron de Madrid
Pozuelo de Alarcón, Madrid, Spain
Hospital Universitario Virgen de La Arrixaca
El Palmar, Murcia, Spain
National Taiwan Uni Hospital
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.